Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

Regulatory T cells (Treg cells) are a small subset of immune cells that are dedicated to
curbing excessive immune activation and maintaining immune homeostasis. Accordingly …

Regulatory T (Treg) cells suppress inflammation and regulate immune system activity. In
patients with systemic or organ-specific autoimmune diseases or those receiving …

Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …

Background Dysfunction of regulatory T (Treg) cells has been detected in diverse
inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is …

With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …

Acute graft-versus-host disease (aGVHD) is associated with high risk of morbidity and
mortality and is a common complication after double umbilical cord blood (UCB) …

Posttransplant relapse is still the major cause of treatment failure in high-risk acute
leukemia. Attempts to manipulate alloreactive T cells to spare normal cells while killing …

▪ Abstract Naturally occurring CD4+ regulatory T cells, the majority of which express CD25,
are engaged in dominant control of self-reactive T cells, contributing to the maintenance of …

Mature donor T cells cause graft-versus-host disease (GVHD), but they are also the main
mediators of the beneficial graft-versus-tumor (GVT) activity of allogeneic bone marrow …